Usefulness of Once-Weekly GLP-1 Receptor Agonist Semaglutide on Glycemic Control in Subjects with Type 2 Diabetes Mellitus: Switching from the Same Class Dulaglutide in a Retrospective Observation Study

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2024 Jan 15

PMID 38223524

Authors

Tomohiko Kimura

Masato Kubo

Kaio Takahashi

Ryo Wamata

Yuichiro Iwamoto

Hideyuki Iwamoto

Yukino Katakura

Junpei Sanada

Yoshiro Fushimi

Masashi Shimoda

Fuminori Tatsumi

Shuhei Nakanishi

Tomoatsu Mune

Kohei Kaku

Hideaki Kaneto

Affiliations

Soon will be listed here.

Abstract

Recently, the development of once-weekly incretin-based injections dulaglutide and semaglutide has drawn a great deal of attention. This study is aimed at comparing the efficacy of once-weekly GLP-1 receptor activator (GLP-1RA) dulaglutide and semaglutide on glycemic control and several metabolic parameters in patients with type 2 diabetes mellitus. We compared various clinical parameters between before and after switching from dulaglutide to semaglutide in "study 1" (pre-post comparison) and set the control group using propensity score matching method in "study 2." In "study 1," six months after the switching, HbA1c was significantly reduced from 8.2% to 7.6% and body mass index was also decreased from 30.4 kg/m to 30.0 kg/m. Such effects were more pronounced in subjects whose glycemic control was poor. In "study 2," after 1 : 1 propensity score matching, glycemic control and body weight management were improved in the switching group compared with the dulaglutide continuation group. In this study including obese subjects with poor glycemic control, switching dulaglutide to semaglutide showed more beneficial effects on both glycemic and weight control irrespective of age, body weight, and diabetes duration. Therefore, we should bear in mind that it would be better to start using a relatively new once-weekly GLP-1RA semaglutide in clinical practice, especially in obese subjects with poor glycemic control with other GLP-1RAs.

Citing Articles

Long-Term Clinical and Economic Effects of Switching to Once-Weekly Semaglutide from Other GLP-1 RAs Among Patients with Type 2 Diabetes in China: A Modeling Projection Study.

Hu Y, Chen X, Zou H, Zhang H, Ni Q, Li Y Adv Ther. 2024; 42(2):904-917.

PMID: 39680313 DOI: 10.1007/s12325-024-03082-7.

References

Pratley R, Aroda V, Lingvay I, Ludemann J, Andreassen C, Navarria A . Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6(4):275-286. DOI: 10.1016/S2213-8587(18)30024-X. View

Zheng S, Roddick A, Aghar-Jaffar R, Shun-Shin M, Francis D, Oliver N . Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018; 319(15):1580-1591. PMC: 5933330. DOI: 10.1001/jama.2018.3024. View

Jain A, Kanters S, Khurana R, Kissock J, Severin N, Stafford S . Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study. Diabetes Ther. 2020; 12(2):527-536. PMC: 7846659. DOI: 10.1007/s13300-020-00984-x. View

Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen M, Tuomi T . Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000; 49(6):975-80. DOI: 10.2337/diabetes.49.6.975. View

Reaney M, Yu M, Lakshmanan M, Pechtner V, Van Brunt K . Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials. Diabetes Obes Metab. 2015; 17(9):896-903. DOI: 10.1111/dom.12527. View

Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M . Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. J Diabetes Investig. 2018; 10(3):699-705. PMC: 6497607. DOI: 10.1111/jdi.12906. View

Kimura T, Obata A, Shimoda M, Hirukawa H, Kanda-Kimura Y, Nogami Y . Durability of protective effect of dulaglutide on pancreatic β-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure. Diabetes Metab. 2018; 44(3):250-260. DOI: 10.1016/j.diabet.2017.10.007. View

Sanada J, Kimura T, Shimoda M, Tomita A, Fushimi Y, Kinoshita T . Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study. Front Endocrinol (Lausanne). 2021; 12:714447. PMC: 8415741. DOI: 10.3389/fendo.2021.714447. View

Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S . Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28(2):103-17. DOI: 10.1016/0168-8227(95)01064-k. View

10.

Fukushima M, Usami M, Ikeda M, Nakai Y, Taniguchi A, Matsuura T . Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004; 53(7):831-5. DOI: 10.1016/j.metabol.2004.02.012. View

11.

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

12.

. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2021; 45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010. View

13.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

14.

Zhang C, Kaye J, Cai Z, Wang Y, Prescott S, Liberles S . Area Postrema Cell Types that Mediate Nausea-Associated Behaviors. Neuron. 2020; 109(3):461-472.e5. PMC: 7864887. DOI: 10.1016/j.neuron.2020.11.010. View

15.

Nauck M, Meier J . MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. Eur J Endocrinol. 2019; 181(6):R211-R234. DOI: 10.1530/EJE-19-0566. View

16.

Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M . The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011; 54(5):1098-108. PMC: 3071950. DOI: 10.1007/s00125-011-2069-9. View

17.

Almandoz J, Lingvay I, Morales J, Campos C . Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clin Diabetes. 2020; 38(4):390-402. PMC: 7566932. DOI: 10.2337/cd19-0100. View

18.

Kimura T, Kaneto H, Shimoda M, Hirukawa H, Okauchi S, Kohara K . Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes. Mol Cell Endocrinol. 2014; 400:78-89. DOI: 10.1016/j.mce.2014.11.018. View

19.

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

20.

Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T . Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015; 17(10):974-83. PMC: 5042083. DOI: 10.1111/dom.12534. View